You are here

Microhydrogel Depot for Sustained Delivery of Prophylactic Bioscavenger

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-13-P-0170
Agency Tracking Number: C131-107-0066
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD13-107
Solicitation Number: 2013.1
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-05-01
Award End Date (Contract End Date): 2013-10-31
Small Business Information
1 Riverside Circle Suite 400
Roanoke, VA -
United States
DUNS: 627132913
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Zhiguo Zhou
 Principal Investigator
 (434) 483-4234
Business Contact
 Maggie Hudson
Title: Senior Contracts Administrator
Phone: (434) 483-4254
Research Institution

Neurotoxic organophosphorus (OP) agents (e.g. sarin, soman, VX and tabun) were developed initially as pesticides and adapted for chemical warfare. OP agents are fast acting and lethal at even very low doses. Countering the threat of intoxication by OP nerve agents is an important mission for homeland security. Currently, the most promising strategy to counter OP intoxication is to scavenge the agents using injectable butyrylcholinesterase. BuChE has low substrate specificity and thus may offer a broad spectrum protection against OP agents by irreversible binding to the toxins. Human plasma-derived BuChE is effective but it is difficult to produce large quantities. Recombinant BuChE lack the necessary stability and extended circulation over sufficient periods to provide adequate prophylaxis while minimizing the need for repeated administration. Luna proposes to develop a microhydrogel-based physiological depot for long-term delivery of recombinant BuChE at proper release rates. The intramuscularly injectable depot will be able to maintain BuChE plasma concentration that is effective to bioscavenger OP agents for multiple weeks. Phase I will demonstrate the technical feasibility using in vitro assays assisted by computational modeling and Phase II will demonstrate the depot performance in appropriate animal models in preparation of IND filing.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government